Assembly Biosciences, Inc. (ASMB)
20.13
-0.73
(-3.50%)
USD |
NASDAQ |
Oct 30, 16:00
20.19
+0.06
(+0.30%)
After-Hours: 20:00
Assembly Biosciences Net Income (Quarterly) : -3.857M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.857M |
| March 31, 2026 | -9.079M |
| December 31, 2025 | 22.09M |
| September 30, 2025 | -9.196M |
| June 30, 2025 | -10.20M |
| March 31, 2025 | -8.818M |
| December 31, 2024 | -10.34M |
| September 30, 2024 | -9.613M |
| June 30, 2024 | -11.15M |
| March 31, 2024 | -9.077M |
| December 31, 2023 | -10.96M |
| September 30, 2023 | -14.42M |
| June 30, 2023 | -16.90M |
| March 31, 2023 | -18.95M |
| December 31, 2022 | -22.40M |
| September 30, 2022 | -23.14M |
| June 30, 2022 | -24.46M |
| March 31, 2022 | -23.09M |
| December 31, 2021 | -60.26M |
| September 30, 2021 | -18.80M |
| June 30, 2021 | -23.60M |
| March 31, 2021 | -27.20M |
| December 31, 2020 | -39.42M |
| September 30, 2020 | -3.349M |
| June 30, 2020 | 7.27M |
| Date | Value |
|---|---|
| March 31, 2020 | -26.66M |
| December 31, 2019 | -27.08M |
| September 30, 2019 | -25.00M |
| June 30, 2019 | -18.50M |
| March 31, 2019 | -27.05M |
| December 31, 2018 | -26.16M |
| September 30, 2018 | -21.54M |
| June 30, 2018 | -26.81M |
| March 31, 2018 | -16.25M |
| December 31, 2017 | -3.007M |
| September 30, 2017 | -12.27M |
| June 30, 2017 | -13.60M |
| March 31, 2017 | -13.93M |
| December 31, 2016 | -11.55M |
| September 30, 2016 | -11.57M |
| June 30, 2016 | -10.15M |
| March 31, 2016 | -10.99M |
| December 31, 2015 | -7.748M |
| September 30, 2015 | -6.618M |
| June 30, 2015 | -6.943M |
| March 31, 2015 | -7.145M |
| December 31, 2014 | -6.229M |
| September 30, 2014 | -11.02M |
| June 30, 2014 | -2.469M |
| March 31, 2014 | -4.070M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 2.429B |
| BridgeBio Pharma, Inc. | -60.50M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 13.37M |
| Total Expenses (Quarterly) | 17.23M |
| EPS Diluted (Quarterly) | -0.2046 |
| Enterprise Value | 81.58M |
| Gross Profit Margin (Quarterly) | 99.85% |
| Profit Margin (Quarterly) | -28.84% |
| Earnings Yield | -0.37% |
| Normalized Earnings Yield | -0.3651 |